查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602655

Alpha1 抗胰蛋白酶缺乏症治疗药物市场：按治疗方法、给药途径和分销管道 - 全球预测 2025-2030

Alpha 1 Antitrypsin Deficiency Treatment Market by Treatment (Augmentation Therapy, Bronchodilators, Corticosteroids), Route of Administration (Inhalation, Injection, Oral), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

Alpha1抗胰蛋白酶缺乏症治疗药物市场2023年估值为30.2亿美元，预计2024年将达到32.6亿美元，复合年增长率为9.15%，2030年将达到55.7亿美元，预计将达到1000万美元。

α-1 抗胰蛋白酶缺乏症 (AATD) 是一种遗传性疾病，其特征是蛋白质 α-1 抗胰蛋白酶含量不足，会导致肺部和肝臟併发症。 AATD 治疗市场包括蛋白质替代疗法、基因疗法和其他旨在控制症状和减缓疾病进展的药物干预措施。 AATD 的潜在严重性强调了对这些治疗的需求，如果不治疗，可能会导致慢性阻塞性肺病(COPD) 和肝硬化。最终使用者包括进行这些治疗的医院、专科诊所和居家医疗机构。市场成长受到意识提高、基因研究进步和诊断工具可用性增加的影响。最近的商机包括基因治疗的进步，特别是 CRISPR-Cas9 技术。人口老化和慢性阻塞性肺病患者数量的增加将进一步推动市场需求。然而，治疗成本高、新兴地区认知度低以及基因治疗的复杂性等障碍对市场成长构成了挑战。此外，监管障碍和缺乏全面的患者资料可能会阻碍药物开发和核准过程。创新机会包括扩大基因编辑研究以及开发侵入性较小且具成本效益的治疗方法。生物技术公司和学术机构之间的合作对于加速创新和临床试验以及将新治疗方法推向市场至关重要。 AATD 治疗市场的本质是动态但小众的，重点是精准医疗。寻求发展业务的公司应专注于研发投资、策略伙伴关係和市场教育倡议，以加深患者参与并优化治疗结果。透过解决这些领域的问题，我们可以释放新的市场潜力，同时为 AATD 管理方面的有意义的进步做出贡献。

主要市场统计
基准年[2023] 30.2亿美元
预测年份 [2024] 32.6亿美元
预测年份 [2030] 55.7亿美元
复合年增长率（%） 9.15%

市场动态：快速发展的 Alpha1-抗胰蛋白酶缺乏症治疗市场的关键市场洞察

供需的动态交互作用正在改变 α-1 抗胰蛋白酶缺乏症药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 族群中α1抗胰蛋白酶缺乏症增加
    • 提高早期诊断和预防保健的意识
  • 市场限制因素
    • 研发高成本且缺乏熟练的专业人员
  • 市场机会
    • 开始研究新的 α-1 抗胰蛋白酶缺乏症治疗方法
    • 增加对医疗基础设施现代化的投资
  • 市场挑战
    • α1 抗胰蛋白酶缺乏症诊断的局限性

波特五力：开拓 Alpha1-抗胰蛋白酶缺乏药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 Alpha1-抗胰蛋白酶缺乏症治疗药物市场的外部影响

外部宏观环境因素在塑造 Alpha1 抗胰蛋白酶缺乏治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解α1-抗胰蛋白酶缺乏症治疗药物市场的竞争状况

对 Alpha1-抗胰蛋白酶缺乏症治疗药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵 α1 抗胰蛋白酶缺乏症治疗药物市场供应商的绩效评估

FPNV定位矩阵是评估α1-抗胰蛋白酶缺乏疗法市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，为 Alpha1-抗胰蛋白酶缺乏症治疗药物市场的成功指明道路

对于希望加强在全球市场的影响力的公司来说，对 Alpha1 抗胰蛋白酶缺乏症治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人群中 α-1 抗胰蛋白酶缺乏症的发生率不断增加
      • 提高早期诊断和预防保健的意识
    • 抑制因素
      • 研发成本高，缺乏熟练的专业人员
    • 机会
      • 新型 α-1 抗胰蛋白酶缺乏症治疗方法的新研究
      • 增加对现代化医疗基础设施的投资
    • 任务
      • α1-抗胰蛋白酶缺乏症诊断的局限性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 Alpha1 抗胰蛋白酶缺乏症治疗药物市场（依治疗）

  • 强化治疗
  • 支气管扩张剂
  • 皮质类固醇
  • 氧气疗法

第七章 Alpha1 抗胰蛋白酶缺乏症治疗药物市场：依给药途径

  • 吸入
  • 注射
  • 口服

第八章 Alpha1 抗胰蛋白酶缺乏症治疗药物市场：按分销管道

  • 离线
    • 医院药房
    • 零售药房
  • 在线的

第九章北美和南美Alpha1抗胰蛋白酶缺乏症治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区Alpha1抗胰蛋白酶缺乏症治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的α1-抗胰蛋白酶缺乏症治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abeona Therapeutics Inc
  • Alnylam Pharmaceuticals, Inc.
  • Apic Bio
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Cedars-Sinai Health System
  • Centessa Pharmaceuticals PLC
  • Chiesi Farmaceutici SpA
  • CSL Limited
  • Curaxys SL
  • Dicerna Pharmaceuticals, Inc
  • GlaxoSmithKline PLC
  • Grifols, SA
  • Inhibrx, Inc.
  • Intellia Therapeutics, Inc.
  • Kamada Ltd.
  • Krystal Biotech, Inc.
  • LFB Biomedicaments SA
  • Mereo Biopharma Group PLC
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • PH PHARMA CO. LTD
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-C002B1C99847

The Alpha 1 Antitrypsin Deficiency Treatment Market was valued at USD 3.02 billion in 2023, expected to reach USD 3.26 billion in 2024, and is projected to grow at a CAGR of 9.15%, to USD 5.57 billion by 2030.

Alpha 1 Antitrypsin Deficiency (AATD) is a genetic disorder characterized by inadequate levels of the protein alpha-1 antitrypsin, leading to lung and liver complications. The treatment market for AATD encompasses protein replacement therapies, gene therapies, and other pharmaceutical interventions aimed at managing symptoms and slowing disease progression. The necessity of these treatments is underscored by the potential severity of AATD, which can result in chronic obstructive pulmonary disease (COPD) and liver cirrhosis if untreated. End-users include hospitals, specialty clinics, and home care settings where these treatments are administered. Market growth is influenced by rising awareness, advancements in genetic research, and the increasing availability of diagnostic tools. Recent opportunities focus on gene therapy advancements, specifically CRISPR-Cas9 technologies, which offer potential curative treatments rather than merely addressing symptoms. The aging population and rise in COPD cases further drive market demand. However, barriers such as high treatment costs, limited awareness in emerging regions, and the complexity of gene therapies challenge market growth. Moreover, regulatory hurdles and the scarcity of comprehensive patient data can impede drug development and approval processes. For innovation, expanding research into gene editing and the development of less invasive, cost-effective treatment options present lucrative opportunities. Collaborations between biotech firms and academic institutions can accelerate innovation and clinical trials, crucial for bringing new therapies to market. The nature of the AATD treatment market is dynamic yet niche, emphasizing precision medicine. Companies aiming for business growth should focus on R&D investment, strategic partnerships, and market education initiatives to deepen patient engagement and optimize treatment outcomes. Addressing these areas can unlock new market potentials while contributing to meaningful advancements in AATD management.

KEY MARKET STATISTICS
Base Year [2023] USD 3.02 billion
Estimated Year [2024] USD 3.26 billion
Forecast Year [2030] USD 5.57 billion
CAGR (%) 9.15%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Alpha 1 Antitrypsin Deficiency Treatment Market

The Alpha 1 Antitrypsin Deficiency Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of alpha 1 antitrypsin deficiency among population
    • Growing awareness about early diagnosis and preventive care
  • Market Restraints
    • High costs associated with R&D and dearth of skilled professionals
  • Market Opportunities
    • Emerging research on new alpha 1 antitrypsin deficiency treatments
    • Increasing investments to modernize healthcare infrastructure
  • Market Challenges
    • Limitations associated with a diagnosis of alpha 1 antitrypsin deficiency

Porter's Five Forces: A Strategic Tool for Navigating the Alpha 1 Antitrypsin Deficiency Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Alpha 1 Antitrypsin Deficiency Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Alpha 1 Antitrypsin Deficiency Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Alpha 1 Antitrypsin Deficiency Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Alpha 1 Antitrypsin Deficiency Treatment Market

A detailed market share analysis in the Alpha 1 Antitrypsin Deficiency Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Alpha 1 Antitrypsin Deficiency Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Alpha 1 Antitrypsin Deficiency Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Alpha 1 Antitrypsin Deficiency Treatment Market

A strategic analysis of the Alpha 1 Antitrypsin Deficiency Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Alpha 1 Antitrypsin Deficiency Treatment Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc, Alnylam Pharmaceuticals, Inc., Apic Bio, Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Baxter International Inc., Cedars-Sinai Health System, Centessa Pharmaceuticals PLC, Chiesi Farmaceutici S.p.A., CSL Limited, Curaxys S.L., Dicerna Pharmaceuticals, Inc, GlaxoSmithKline PLC, Grifols, S.A., Inhibrx, Inc., Intellia Therapeutics, Inc., Kamada Ltd., Krystal Biotech, Inc., LFB Biomedicaments S.A., Mereo Biopharma Group PLC, Novo Nordisk A/S, Pfizer, Inc., PH PHARMA CO. LTD, Takeda Pharmaceutical Company Limited, and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Alpha 1 Antitrypsin Deficiency Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Augmentation Therapy, Bronchodilators, Corticosteroids, and Oxygen Therapy.
  • Based on Route of Administration, market is studied across Inhalation, Injection, and Oral.
  • Based on Distribution Channel, market is studied across Offline and Online. The Offline is further studied across Hospital Pharmacy and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of alpha 1 antitrypsin deficiency among population
      • 5.1.1.2. Growing awareness about early diagnosis and preventive care
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with R&D and dearth of skilled professionals
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging research on new alpha 1 antitrypsin deficiency treatments
      • 5.1.3.2. Increasing investments to modernize healthcare infrastructure
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations associated with a diagnosis of alpha 1 antitrypsin deficiency
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Alpha 1 Antitrypsin Deficiency Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Augmentation Therapy
  • 6.3. Bronchodilators
  • 6.4. Corticosteroids
  • 6.5. Oxygen Therapy

7. Alpha 1 Antitrypsin Deficiency Treatment Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhalation
  • 7.3. Injection
  • 7.4. Oral

8. Alpha 1 Antitrypsin Deficiency Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Offline
    • 8.2.1. Hospital Pharmacy
    • 8.2.2. Retail Pharmacy
  • 8.3. Online

9. Americas Alpha 1 Antitrypsin Deficiency Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc
  • 2. Alnylam Pharmaceuticals, Inc.
  • 3. Apic Bio
  • 4. Arrowhead Pharmaceuticals, Inc.
  • 5. AstraZeneca PLC
  • 6. Baxter International Inc.
  • 7. Cedars-Sinai Health System
  • 8. Centessa Pharmaceuticals PLC
  • 9. Chiesi Farmaceutici S.p.A.
  • 10. CSL Limited
  • 11. Curaxys S.L.
  • 12. Dicerna Pharmaceuticals, Inc
  • 13. GlaxoSmithKline PLC
  • 14. Grifols, S.A.
  • 15. Inhibrx, Inc.
  • 16. Intellia Therapeutics, Inc.
  • 17. Kamada Ltd.
  • 18. Krystal Biotech, Inc.
  • 19. LFB Biomedicaments S.A.
  • 20. Mereo Biopharma Group PLC
  • 21. Novo Nordisk A/S
  • 22. Pfizer, Inc.
  • 23. PH PHARMA CO. LTD
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 190. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023